Comprehensive Overview

According to Frost & Sullivan's data, the global oncology drug market increased sharply from $83.2 billion in 2015 to $143.5 billion in 2019, with a compound annual growth rate of 14.6%. The Group is an Asia-Pacific clinical stage biopharmaceutical company focusing on innovative anti-tumor drugs. As of the end of October, the Group had set up an innovative R&D pipeline with 12 oncological drug assets, including 2 advanced clinical products, but no assets on the commercialization stage.

Risk Factors

Drug development investment is highly speculative, requires significant upfront capital expenditure, and there is a huge risk that candidate drugs will not obtain regulatory approval or are not commercially viable. Since the establishment of the group, the group has lost money in every period since its establishment, and it is anticipated that major losses will continue to occur in the foreseeable future.